Abstract 1958P
Background
HN-STS is a challenging disease due to its diverse clinical presentation. In an attempt to refine the prognostication of these pts, the AJCC in its 8th edition proposed a new dedicated T staging group based on cutoffs of 2 and 4 cm for classifying T1, T2 and T3, and surrounding tissue invasion as T4, as opposed to the dichotomic T1-T2 5cm cutoff adopted by the 7th AJCC.
Methods
This is a retrospective study of pts diagnosed with nonmetastatic HN-STS treated with curative intent in a single tertiary hospital, approved by the institutional ethical review committee. The aim was to compare the 8th AJCC T staging to the previous classification as a prognostic tool for HN-STS, added to other variables such as age, histological subtype, grade and regional lymph node metastasis (LNM). AJCC 7th and 8th have been compared regarding T staging with Cohen’s kappa coefficient (KC) using inter-rater agreement analysis. The Kaplan-Meier estimator was used to calculate median survival time and differences in time-to-event outcomes were assessed using the log-rank test. Cox proportional hazard model was used to assess the effect of features in overall survival (OS).
Results
From 1997 to 2000, 135 pts were identified in institutional archives. Sarcoma NOS (N=50) and Leiomyosarcoma (N=17) were the most common histologic subtypes, as well as high-grade tumors (N=85). KC of inter-rater agreement was 0.46, statistically significant (p=0.03), indicating poor agreement between both T staging systems. Regarding OS, AJCC 7th (T1 and T2) and 8th (T1, T2, T3 and T4) T size stratification was not statistically different (P=0.42 and P=0.27, respectively). High-grade (71.4% vs 93.6%, P=0.005) and regional LNM (31.3% vs 81.4%, P=0.008) had worse 5-year OS in Cox multivariate analysis. Pts with tumor size>4cm or local invasion, high grade and LNM had 2.30, 7.11 and 4.37-fold increased risk of death respectively.
Conclusions
In our series, neither 7th nor 8th AJCC T size classifications adequately stratified prognostic groups or correlated survival for HN-STS pts. The 8th AJCC T4, the high-grade tumors and regional LNM demonstrated significant worse prognostic impact in pts harboring HN-STS.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
1929P - phase II results from the RINGSIDE phase II/III trial of AL102 for treatment of desmoid tumors
Presenter: Bernd Kasper
Session: Poster session 15
1930P - phase II trial of avelumab in combination with gemcitabine in advanced leiomyosarcoma as a second-line treatment (KCSG UN18-06)
Presenter: Young Saing Kim
Session: Poster session 15
1931P - Ultra-rare sarcomas have worse survival compared to non-ultra-rare sarcomas: A national cancer registry study
Presenter: MIng-Jing Lee
Session: Poster session 15
1932P - First in human trial of CEB-01 for retroperitoneal soft tissue sarcoma
Presenter: Jose Antonio González
Session: Poster session 15
1933P - Perioperative chemotherapy could reduce the risk of recurrence in resected leiomyosarcoma of the vena cava (LMS-VC): A retrospective bi-centric series on 41 patients
Presenter: Thibaud Bertrand
Session: Poster session 15
1934P - Pharmacokinetics of unesbulin in a phase Ib study of patients with advanced leiomyosarcoma
Presenter: Brian Van Tine
Session: Poster session 15
1935P - Exploration of tertiary lymphatic structure in soft tissue sarcoma for the prognostic and immunotherapy response
Presenter: Wang Xiang-Xu
Session: Poster session 15
1936P - Targeted therapy of desmoplastic small round cell tumor guided by multilayered molecular profiling
Presenter: Marcus Renner
Session: Poster session 15
1937P - KM-subtraction meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma
Presenter: Qin Jian Low
Session: Poster session 15
1938P - Assessment of clinical benefit of cancer drugs recommended in National Comprehensive Cancer Network (NCCN) guidelines for advanced soft tissue sarcomas (STS) and bone sarcomas (BS)
Presenter: Maria Aguado Sorolla
Session: Poster session 15